Michelsen, Brigitte http://orcid.org/0000-0003-0103-2840
Berget, Kristine Thomassen
Kavanaugh, Arthur http://orcid.org/0000-0001-6942-5830
Haugeberg, Glenn http://orcid.org/0000-0002-9279-5191
Funding for this research was provided by:
Norsk Revmatikerforbund
Pfizer
Calpro AS
Article History
Received: 22 March 2022
Accepted: 7 May 2022
First Online: 20 May 2022
Funding
: The study was supported by the Norwegian Rheumatism Association, who also funded the journal’s Rapid Service Fee. The iLite™ assay kits and Victor™ X (PerkinElmer) luminometer were provided from Pfizer free of charge. The Calpro™ (ALP) ELISA kits were donated from Calpro AS free of charge. Pfizer, Calpro, and the Norwegian Rheumatism Association had no influence on the data collection, statistical analyses, writing of the manuscript, or decision to submit.
: All coauthors were responsible for study design. Brigitte Michelsen, Kristine Thomassen Berget, and Glenn Haugeberg were responsible for data acquisition. Brigitte Michelsen analyzed the data and wrote the first version of the manuscript. All authors critically revised the manuscript and approved the final version.
: Brigitte Michelsen: Consultancy fees from Novartis. Grant/research support from Novartis and Pfizer paid to employer. Kristine Thomassen Berget: None. Arthur Kavanaugh: None. Glenn Haugeberg: Unrestricted grant from Pfizer.
: The study was approved by the Regional Committees for Medical and Health Research Ethics mid-Norway (Ref. 2015/1196/REK midt). Written informed consent was obtained from each patient prior to inclusion in the study. The study was performed in accordance with the Helsinki Declaration.
: All data generated or analyzed during this study are included in this published article/as supplementary information files.